TY - T1的回答:生存和肺function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00283-2021 VL - 57 IS - 3 SP - 2100283 AU - Behr, Jürgen AU - Pittrow, David AU - Klotsche, Jens Y1 - 2021/03/01 UR - //www.qdcxjkg.com/content/57/3/2100283.abstract N2 - We thank S. Suissa and D. Assayag, as well as J. Borchardt, for their interest in our study and for giving us the opportunity to respond to their comments regarding the potential impact of immortal time bias and lead time bias on the observed difference between idiopathic pulmonary fibrosis (IPF) patients treated with or without antifibrotic drugs under real-life conditions. As a key finding of the INSIGHTS-IPF Registry follow-up analysis, we had reported that survival was significantly higher in IPF patients receiving antifibrotic therapy when compared with propensity-matched IPF patients not receiving such drugs [1].Survival differences favouring antifibrotic therapy from INSIGHTS-IPF registry data are not compromised by immortal and lead time biases https://bit.ly/3tDpk1S ER -